Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HRS-3095 in Chronic Spontaneous Urticaria
NCT07613866Phase 2Not yet recruiting
- Sponsor
- Chengdu Suncadia Pharmaceuticals
- Start
- Jul 2026
- Primary completion
- Dec 2026
- Countries
- 1
01
Overview
A Phase 2 trial of HRS-3095 in chronic spontaneous urticaria (CSU), sponsored by Chengdu Suncadia Pharmaceuticals. Planned start Jul 2026; status: not yet recruiting.
02
Drugs
HRS-3095
03
Conditions
chronic spontaneous urticaria (CSU)
Beyond the preview
Go deeper on NCT07613866.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07613866.